Sanofi

Sanofi is a research & development-driven, AI-powered healthcare biopharma company committed to improving lives through innovative medicines & vaccines. It operates globally, focusing on various therapeutic areas and vaccine development.

Positive signals

Sanofi has set a target to achieve net-zero carbon emissions by 2050, demonstrating a long-term commitment to environmental sustainability and climate action.

Source →

Sanofi has made significant progress in reducing its carbon emissions and is actively pursuing sustainability projects aimed at improving energy efficiency across its operations.

Source →

Sanofi's ESG rating is 70/100 according to Sustainalytics, reflecting strong performance in environmental sustainability, social responsibility, and governance practices relative to industry peers.

Source →

Sanofi's ESG risk management is considered robust, with the company actively addressing material ESG issues such as ethical business practices, environmental impact, and access to healthcare.

Source →

Sanofi is recognized for its commitment to health equity and the development of treatments for critical conditions, with a focus on improving access to medicines in underserved regions.

Source →

Concerns

Sanofi's ESG risk rating has been impacted by controversy levels in the last three years, as tracked by Sustainalytics, indicating ongoing reputational or operational risks.

MEDIUM

Source →

Sanofi has faced criticism over its drug pricing practices, raising concerns about the affordability and accessibility of its treatments, particularly in lower-income markets.

HIGH

Source →

Sanofi's ESG risk profile includes exposure to risks from manufacturing activities and the handling of hazardous materials, which could lead to environmental or safety incidents if not properly managed.

MEDIUM

Source →

Sanofi has been involved in controversies related to vaccine access, with advocacy groups highlighting issues around equitable distribution and availability in certain regions.

MEDIUM

Source →

Sanofi

Positive signals

Sanofi has set a target to achieve net-zero carbon emissions by 2050, demonstrating a long-term commitment to environmental sustainability and climate action.

Sanofi has made significant progress in reducing its carbon emissions and is actively pursuing sustainability projects aimed at improving energy efficiency across its operations.

Sanofi's ESG rating is 70/100 according to Sustainalytics, reflecting strong performance in environmental sustainability, social responsibility, and governance practices relative to industry peers.

Sanofi's ESG risk management is considered robust, with the company actively addressing material ESG issues such as ethical business practices, environmental impact, and access to healthcare.

Sanofi is recognized for its commitment to health equity and the development of treatments for critical conditions, with a focus on improving access to medicines in underserved regions.

Concerns

Sanofi's ESG risk rating has been impacted by controversy levels in the last three years, as tracked by Sustainalytics, indicating ongoing reputational or operational risks.

Sanofi has faced criticism over its drug pricing practices, raising concerns about the affordability and accessibility of its treatments, particularly in lower-income markets.

Sanofi's ESG risk profile includes exposure to risks from manufacturing activities and the handling of hazardous materials, which could lead to environmental or safety incidents if not properly managed.

Sanofi has been involved in controversies related to vaccine access, with advocacy groups highlighting issues around equitable distribution and availability in certain regions.

Alternatives